A Trial of a Transglutaminase 2 Inhibitor in Celiac Disease. Reply

MLA

Knut E.A. Lundin, et al. “A Trial of a Transglutaminase 2 Inhibitor in Celiac Disease. Reply.” The New England Journal of Medicine, vol. 385, no. 16, Oct. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7028f4e3a76cb012a02b9af1fd88abd4&authtype=sso&custid=ns315887.

APA

Knut E.A. Lundin, Markku Mäki, & Detlef Schuppan. (2021). A Trial of a Transglutaminase 2 Inhibitor in Celiac Disease. Reply. The New England Journal of Medicine, 385(16).

Chicago

Knut E.A. Lundin, Markku Mäki, and Detlef Schuppan. 2021. “A Trial of a Transglutaminase 2 Inhibitor in Celiac Disease. Reply.” The New England Journal of Medicine 385 (16). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7028f4e3a76cb012a02b9af1fd88abd4&authtype=sso&custid=ns315887.